Aerolid

Quick links to important sections

Aerolid

Treatment option: Asthma, Bronchospasm

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aerolid

Aerolid is a prescription-only medication whose identity is centered on the active pharmaceutical ingredient, Flunisolide. This drug is a single-ingredient synthetic agent used exclusively via the respiratory route.

Property Description
Active ingredient Flunisolide (as Flunisolide hemihydrate)
Form Inhalation Aerosol / Aqueous Nasal Spray Solution
Pharmacological class Corticosteroid / Glucocorticoid
Common use Prophylactic maintenance of inflammation
Origin Synthetic

What Type of Medicine is Aerolid? (Classification and Origin)

Aerolid is fundamentally classified as a synthetic corticosteroid, specifically belonging to the glucocorticoid pharmacological class. The active component, Flunisolide, is an artificially synthesized chemical entity. Flunisolide is designed to mimic naturally occurring glucocorticoid hormones, primarily by acting as a strong anti-inflammatory agent. The compound possesses high topical potency, which supports its utility in managing chronic respiratory conditions where inflammation is a factor.


Aerolid's Forms and General Therapeutic Purpose

Aerolid is supplied in specialized preparations designed for targeted delivery, principally as an Inhalation Aerosol (metered-dose inhaler) and an Aqueous Nasal Spray Solution. These specialized dosage forms facilitate either Inhalation (pulmonary) or Intranasal administration, ensuring the drug reaches the affected mucous membranes directly. As a locally acting glucocorticoid, Flunisolide acts to reduce the severity of inflammatory mediators. This localized effect means the drug's primary function is to provide prophylactic therapy, or maintenance treatment, aimed at suppressing the chronic swelling and irritation that leads to respiratory symptoms, such as persistent nasal congestion.


Summary of Core Aerolid Identity

Aerolid is defined by the compound Flunisolide, a synthetic corticosteroid delivered via specific inhalation or nasal forms. Its primary role is to provide powerful, localized anti-inflammatory control, acting as a scheduled maintenance treatment designed for adults and pediatric patients above a specific age threshold.

Regulatory References

  1. NIH: DailyMed – Flunisolide

What side effects are possible with Aerolid?

Possible Side Effects and Safety Information

Flunisolide inhalation aerosol (Aerolid) is an inhaled corticosteroid associated with both local and systemic safety considerations, based on regulatory labeling from the U.S. Food and Drug Administration (FDA).


Common and Local Adverse Reactions

The most commonly reported adverse reactions include pharyngitis, rhinitis, headache, sinusitis, and increased cough. Localized infection with Candida albicans (oral thrush) in the mouth and throat is a potential side effect, and patients are monitored for this risk.

Adverse Reaction Category Frequency Classification Examples
Very Common ge 10% Pharyngitis, Headache, Rhinitis
Common 1% to 10% Vomiting, Dyspepsia, Oral Moniliasis, Migraine, Taste Perversion, Weakness

Serious and Clinically Significant Safety Information

  • Immunosuppression: The drug can suppress the immune system, leading to the potential worsening of existing infections (e.g., fungal, bacterial, viral, parasitic, or ocular herpes simplex). Non-immune individuals exposed to chickenpox or measles may experience a more serious or fatal course of the disease.
  • Adrenal Suppression: Systemic corticosteroid effects, including hypercorticism and adrenal suppression (Hypothalamic-Pituitary-Adrenal, HPA axis suppression), may occur with high dosages or in susceptible individuals. Adrenal insufficiency is a risk, especially during periods of stress, surgery, or trauma, or upon transfer from oral corticosteroids.
  • Ocular Effects: Long-term use may increase the risk of developing glaucoma and cataracts, requiring periodic eye examinations.
  • Bone Density: Decreases in Bone Mineral Density (BMD) have been reported with long-term use of corticosteroids.
  • Pediatric Safety: Growth must be monitored in pediatric patients due to the potential effect of corticosteroids on growth rate.

Safety Restrictions and Limitations

Flunisolide is not indicated for the relief of acute bronchospasm or in status asthmaticus. It must be used with caution in patients with untreated infections, including active or quiescent tuberculosis, and those who have recently had nasal trauma or surgery. Patients being transferred from systemic corticosteroids require slow tapering to mitigate the risk of impaired adrenal function.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that overdose with Aerolid (Flunisolide) is typically associated with the systemic effects of glucocorticoid excess resulting from prolonged use of excessive dosages. This pattern differs from acute toxicity and is defined by a specific physiological change documented in the prescribing information.

Documented Manifestations and Serious Outcomes

The primary physiological manifestation of excessive exposure is the suppression of the hypothalamic-pituitary-adrenal (HPA) axis function. This is the key clinical concern, as it can lead to the severe outcome of acute adrenal insufficiency, particularly when high-dose use is stopped abruptly or when the patient is subjected to physiological stress. Careful monitoring of HPA axis function is required following excessive or prolonged exposure.

Emergency Actions and Management

In the event of suspected overdose, the required action is to seek immediate medical attention or contact a Poison Control Center. Overdose management is based on providing symptomatic and supportive treatment. The official regulatory labels explicitly state that no specific antidote is known for Flunisolide overdose. The necessity for urgent help is triggered by the potential for HPA suppression to result in acute adrenal insufficiency, which is listed as a severe consequence in the official prescribing information.

Therapeutic Uses of Aerolid

Aerolid is a maintenance medication applied to help manage chronic inflammatory processes in the respiratory passages, and is applied across domains where additional symptomatic support is needed. This medication serves as a scheduled, prophylactic controller for persistent respiratory conditions.

This therapy is relevant for managing persistent asthma and for the proactive treatment of both seasonal and perennial allergic rhinitis.

For asthma, this medication is commonly used across conditions presenting with acute episodes and recurrent manifestations. It helps manage the recurring symptoms that include wheezing, persistent coughing, and feelings of chest tightness, which may assist with maintaining functional stability.

For allergic rhinitis, it is relevant for managing symptoms that interfere with daily comfort, such as recurring nasal congestion, runny nose (rhinorrhea), sneezing, and associated itching. This use contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

“This type of scheduled maintenance therapy is used to help patients cope more steadily with difficult episodes and chronic symptom fluctuations.”

Quick Fact: Relevant for Symptoms Related to Inflammatory States

Regulatory References

  1. NIH MedlinePlus overview on Flunisolide Oral Inhalation

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

Aerolid (Flunisolide) is defined for use as a prophylactic maintenance treatment. Its eligibility profile is governed by strict regulatory classifications concerning age, contraindications, and clinical conditions.


Eligibility Scope

Classification Eligible or Restricted Populations
Populations Allowed Adults and Adolescents (ge 12 years); Children ge 6 years of age.
Age-Related Rules Use is not established in children younger than 6 years of age. Older adults require caution due to potential age-related organ changes.
Pregnancy/Lactation Status Pregnancy Category C. Use during lactation requires caution as the drug may pass into breast milk.
Condition-Specific Rules No specific dosage recommendations are defined for patients with renal or hepatic impairment.

Absolute Contraindications and Restrictions

Classification Non-Eligible Groups or Conditional Use
Contraindicated Patients with known hypersensitivity to Flunisolide or any ingredient; Patients experiencing an acute asthma attack or acute bronchospasm.
Use Restricted Patients with untreated systemic infections (e.g., tuberculosis, fungal, viral) or ocular herpes simplex.
Nasal Use Restriction Avoid until healing occurs in patients with recent nasal septal ulcers, surgery, or trauma.

Connection to the overall eligibility profile

The regulatory documents establish eligibility by mandating absolute exclusions for acute respiratory events and hypersensitivity. Further conditional use is imposed by minimum age thresholds and the drug's corticosteroid effects, which necessitate caution in the presence of infections or recent tissue injury.

What should I know about interactions with other medicines?

Aerolid Interactions with Other Medicines and Products

Aerolid (flunisolide, an inhaled corticosteroid) has a lower risk of significant drug interactions compared to corticosteroids taken by mouth because less of the drug is absorbed systemically. However, it is essential to inform your healthcare provider of all prescription, over-the-counter (OTC) medicines, vitamins, and herbal supplements you are currently taking.

Potential Drug Interactions

Interactions may occur when Aerolid is used with other medications, potentially affecting its efficacy or increasing the risk of side effects. While the inhaled route reduces risk, caution is necessary, especially with certain drug classes:

  • Other Corticosteroids: Concomitant use with oral corticosteroids, such as prednisone, may increase the risk of systemic corticosteroid side effects, including adrenal suppression. Your doctor may need to adjust the dose of the oral corticosteroid gradually when starting Aerolid.
  • Drugs Metabolized by the Liver: Medications that inhibit the Cytochrome P450 3A4 (CYP3A4) enzyme (e.g., certain antifungal or antiretroviral drugs) could potentially increase the systemic level of flunisolide. Although not well-studied for inhaled flunisolide, this interaction is a theoretical concern for all inhaled corticosteroids.

Vaccine and Disease Interactions

  • Vaccines: Corticosteroids can weaken the immune system. Patients using Aerolid should consult their doctor before receiving certain vaccines, particularly live vaccines.
  • Other Medical Conditions: Existing conditions like infections (especially viral infections such as ocular herpes simplex), tuberculosis, or osteoporosis may be affected by corticosteroid use. Discussion with your healthcare provider is crucial before using Aerolid if you have these conditions.

Mechanism of Action

Molecular Mechanism and Target

Aerolid is a pharmacodynamic regulator of bone remodeling. It initiates its action by specifically binding to the A1beta-receptor expressed on the surface of osteoclasts. These are the specialized, multi-nucleated cells primarily responsible for bone resorption.

Intracellular Cascade and Physiological Consequence

This binding event triggers a specific downstream signaling cascade within the osteoclast. The resulting intracellular consequence is the modulation and subsequent reduction of NFkappa B activation. By inhibiting this key molecular pathway, Aerolid prevents the full functionality and activity of the osteoclast. This mechanistic action results in the modulation of osteoclast-mediated bone resorption, thereby shifting the overall balance of the physiological bone remodeling process.

Dosage and Administration Information

How to Use Aerolid

Aerolid (Flunisolide) is a controller medication that must be administered on a fixed, scheduled basis and is not indicated for the immediate relief of acute symptoms. Its usage is limited to the respiratory tract via two routes: Oral Inhalation or Intranasal administration, depending on the specific dosage form.

Standard Labeled Dosing Regimens

The standard protocol for use establishes a starting dose that should be reduced to the lowest effective maintenance dose once symptoms are controlled, without exceeding the established maximum daily dose. For adults, the dosing often begins at twice daily (BID) use for both the nasal spray (e.g., two sprays per nostril) and the inhalation aerosol (e.g., two inhalations). The total number of sprays or inhalations administered per day is defined; for example, the nasal spray has a maximum recommended daily dose of up to 8 sprays per nostril.

Administration and Procedural Rules

Proper use requires adherence to specific technical steps. Before the first use or after a period of non-use, the device must be primed by releasing a set number of test sprays into the air. When using the inhalation aerosol, rinsing the mouth with water and discarding it (without swallowing) immediately after administration is a key procedural instruction. For intranasal delivery, the nasal passages should be cleared prior to administering the spray. The full therapeutic effect of this scheduled controller may require up to one to four weeks of continuous, regular use before the benefit is fully observed. Specific lower dose ranges are utilized for pediatric patients (typically children 6 years and older) under the guidance of a healthcare professional.

Recent Clinical Evidence

Research evidence / Overview of studies for Aerolid

Research Supporting Aerolid for Persistent Asthma Maintenance

The clinical evaluation for the inhaled formulation includes Randomized Controlled Trials (RCTs) in adults and children (typically age 6 and older) with persistent asthma. These studies were used in research exploring how symptoms change over time, tracking physical discomfort and functional imbalance, such as lung function markers ( FEV1) and the frequency of wheezing and coughing. Studies also explored how patients using Aerolid were evaluated in trials looking at changes in their need for oral corticosteroid medicines.

Research Supporting Aerolid for Allergic Rhinitis Symptoms

The research for the nasal spray includes Randomized Controlled Trials involving a placebo or other topical agents, studied for conditions associated with acute or disruptive episodes like seasonal and perennial allergic rhinitis. The main goal of this research was to monitor patient-reported outcomes, including the severity of nasal congestion, sneezing frequency, and a runny nose. Comparative studies observed differences in how symptoms evolved in the observed populations receiving the nasal spray versus a comparator.


Evidence Gaps and Areas of Scientific Uncertainty

While substantial evidence is available from controlled trials for the approved uses, certainty remains low regarding consistent long-term effects, as follow-up durations were limited in many controlled trials. Comparative evidence is lacking against all contemporary inhaled or topical steroids. Furthermore, studies monitored outcomes related to systemic function ( HPA axis), which was observed in some studies to indicate a low potential for systemic activity. However, individual systemic exposure may vary, and data for certain groups remain insufficient, meaning results apply only to the populations studied.

Key Studies & References

  1. Flunisolide Oral Inhalation: Official Drug Information
  2. Flunisolide Nasal Spray: Official Drug Label and DailyMed Monograph

Frequently Asked Questions (FAQ)

Common questions about Aerolid (FAQ)


Q: What is the main condition Aerolid is approved by regulatory agencies to treat?

Regulatory documents state that Aerolid (flunisolide) is approved for the maintenance treatment of asthma in its inhalation form. The nasal spray form is also approved for treating allergic rhinitis to relieve symptoms like sneezing, congestion, and a runny nose caused by seasonal or perennial allergies.

Q: Is Aerolid the brand name or the generic name for this medication?

The active ingredient in this medication is flunisolide, which is the generic name. Aerolid is a brand name under which flunisolide has been or is currently marketed, alongside other brand names like AeroBid or Nasarel.

Q: Is a generic version of Aerolid available for prescription?

Yes, generic versions of the medication containing flunisolide are typically available. Official information indicates that lower-cost generic versions may be prescribed depending on the specific dosage form needed.

Q: Why is Aerolid sometimes discussed in connection with a different health problem?

Official information defines flunisolide as a corticosteroid that works primarily by suppressing inflammation. Its mechanism is specifically designed for anti-inflammatory effects in the respiratory or nasal passages, which reflects its approved therapeutic use.

Q: What are the most commonly reported side effects of Aerolid in official documents?

Studies indicate that the most commonly reported side effects (occurring in 1% to 10% of people) include local effects such as nasal burning or stinging and sore throat. Headache and nasal dryness or nosebleeds are also common findings in official documents.

Q: Is there a known risk of a serious, but rare, side effect with Aerolid?

Serious, though rare, side effects mentioned in official warnings include an increased risk of vision problems like cataracts or glaucoma. With long-term or high-dose use, there is also a risk of adrenal gland suppression (where the body does not produce enough of its own steroids).

Q: Can Aerolid cause changes in body weight (gain or loss)?

In some product references, weight gain is listed as a common side effect (1% to 10% of patients). Less commonly, rapid weight gain is also listed as a symptom that may occur with the use of this medication.

Q: Is Aerolid known to cause issues with sleep, such as insomnia or drowsiness?

Regulatory texts mention trouble sleeping (insomnia) as a less common side effect. Furthermore, symptoms like lassitude (a state of weariness) or depression have been reported as possible withdrawal symptoms when switching from oral steroids to this inhaled form.

Q: Are there any digestive side effects commonly associated with taking Aerolid?

Common digestive side effects reported in clinical studies (1% to 10% of patients) include issues such as nausea, vomiting, dyspepsia (indigestion), and abdominal pain. These findings are included in official product information.

Q: Is it common to experience dizziness or headaches when starting Aerolid?

Official product information lists headache as a common side effect of this medication. Dizziness is listed as a less common symptom, often linked to systemic issues like adrenal gland function.

Q: Is it possible to have an allergic-type reaction to Aerolid?

Official warnings classify hypersensitivity (an allergic reaction) to flunisolide or any of its ingredients as a contraindication. Symptoms of a severe allergic reaction, such as hives, difficulty breathing, or swelling, require immediate medical attention.

Q: What should be done if I notice unusual changes or unexpected side effects while on Aerolid?

Official labeling advises consulting a healthcare provider about any adverse events. Information is also available on how to report specific adverse events directly to regulatory bodies like the FDA.

Q: Does long-term use of Aerolid increase the likelihood of experiencing certain side effects?

Using the medication for a long time or in excessive doses may increase the potential for systemic effects. This includes the risk of adrenal gland problems and a decrease in bone mineral density (osteoporosis), according to official warnings.

Q: Does Aerolid interact with common over-the-counter pain medications?

The label generally recommends informing a healthcare provider of all over-the-counter (OTC) medicines being used. Some product references list Aspirin as a potential interaction that may require a dose adjustment determined by a doctor.

Q: Does Aerolid interact with common nutritional or herbal supplements, such as St. John's Wort?

Patients are advised in official warnings to inform their healthcare provider of all herbs and dietary supplements being used. This is because these products may interact with the medicine, although specific supplements are not always detailed in a general warning.

Q: Can Aerolid be taken at the exact same time as other prescribed daily medicines?

Regulatory information focuses on specific known drug-drug interactions that should be avoided. For other non-interacting medicines, general guidance is to discuss the full medicine schedule with a healthcare provider for comprehensive guidance.

Q: Is it safe to consume alcohol in moderation while taking Aerolid?

Official information advises discussing the consumption of alcohol with a healthcare professional as interactions may be possible.

Q: Are there any specific foods or beverages that should be avoided when taking Aerolid?

Official product information generally states that unless a doctor advises otherwise, patients may continue their normal diet. There are typically no blanket restrictions on specific foods or beverages.

Q: How should I proceed if I realize I missed a scheduled dose of Aerolid?

Regulatory documents provide specific guidance for a missed dose, which involves using the dose as soon as possible, or skipping it if the next scheduled dose is near. It is advised not to use a double dose.

Q: Is it safe to crush, split, or chew Aerolid tablets if I have difficulty swallowing pills?

Official product information clarifies that Aerolid (flunisolide) is supplied as an oral inhalation aerosol or a nasal solution. It is not formulated as a common tablet or pill that would be intended for crushing, splitting, or chewing.

Q: Does Aerolid need to be stored at room temperature, or is refrigeration required?

Official guidelines indicate that the medication canister or device is typically stored at room temperature, away from excessive heat and direct light. The product is also advised not to be frozen.

Q: What should be done if I accidentally take a double dose of Aerolid?

Official product information states that suspected overdosage requires immediate contact with emergency resources. This is a standard procedure noted in regulatory documents.

Q: Is Aerolid approved for use in the elderly population?

While specific studies on the geriatric population have not been fully performed, no geriatric-specific problems have been documented in official reviews to date. Caution may be advised for age-related changes in liver or kidney function.

Q: What are the current safety classifications for using Aerolid during pregnancy?

Official warnings indicate that this medication should not be used during pregnancy unless the potential benefits are determined to outweigh the potential risks to the fetus. The decision to use this medication must involve careful consideration of the risks versus the potential benefits, as determined by a healthcare professional.

Q: Is Aerolid considered safe for women who are breastfeeding?

Regulatory documents state that there are no adequate studies to determine infant risk, and it is not known if flunisolide passes into breast milk. The potential benefits of using the drug must be weighed against the potential risks to the nursing infant.

Q: Does having a pre-existing medical condition, such as liver or kidney disease, prevent the use of Aerolid?

Regulatory caution is advised for patients with certain infections (e.g., tuberculosis, ocular herpes simplex) or bone issues (osteoporosis). It is also noted that age-related liver or kidney problems may require caution due to potential impacts on how the body handles the medicine.

Q: Are there any specific populations for whom Aerolid is not recommended in regulatory guidelines?

Official guidelines state that flunisolide is not indicated for children younger than 6 years of age and is contraindicated for patients with a known hypersensitivity to the drug. Caution is also advised for patients with untreated fungal, bacterial, or systemic viral infections.

Q: Is there a potential for developing physical dependence on Aerolid with long-term use?

Regulatory text focuses on the possibility of adrenal insufficiency with long-term or excessive use, which relates to the body's natural steroid production. Patients switching from oral steroids may experience temporary withdrawal symptoms like joint pain or depression.

Q: If I miss a dose of Aerolid, does it affect the overall treatment outcome?

Flunisolide is a controller medication whose effectiveness depends on its regular use. Missing doses can affect its overall therapeutic action because the medication works best when consistent anti-inflammatory action is maintained over time.

Q: Do side effects from Aerolid change if the drug is suddenly stopped?

Patients who were previously treated with systemic corticosteroids and then switch to this inhaled form are advised to be monitored. A sudden change can be accompanied by signs of adrenal insufficiency or withdrawal symptoms, such as joint/muscle pain.

How should Aerolid be stored and disposed of?

The storage and disposal instructions for Aerolid (flunisolide) Nasal Solution are derived exclusively from official regulatory labeling.


Storage Conditions

Aerolid must be stored at Controlled Room Temperature, specifically between 20°C and 25°C (68°F and 77°F), with permitted excursions up to 30°C. The product must be kept in its original container, tightly closed, and stored out of the reach of children and pets [NIH DailyMed: Flunisolide Nasal Solution Label].

Prohibited Environments

It is officially mandated that the nasal solution must not be frozen as this can cause physical damage to the container. The product must also be protected from excess heat and moisture.


Disposal Instructions

Unused or expired Aerolid should not be flushed down the sink or toilet [FDA Disposal Guidance]. The primary method for disposal is through an authorized drug take-back program. If a take-back program is unavailable, the medicine should be mixed with an undesirable material, placed in a sealed bag, and disposed of in the household trash. The bottle must be discarded after the total specified number of sprays has been administered.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aerolid found in:

A-Z Index: